Home/ Stocks/ EWTX

Edgewise Therapeutics, Inc. Common Stock

EWTX XNAS

$43.52 -0.90 (-2.03%) ▼ 15-min delayed

Open

$44.00

High

$44.20

Low

$42.46

Volume

1.48M

Market Cap

$4.78B

About Edgewise Therapeutics, Inc. Common Stock

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 127 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-49,013,000	$-0.46
FY 2025	$0	$-167,795,000	$-1.63
Q3 2025	$0	$-40,666,000	$-0.39
Q2 2025	$0	$-36,115,000	$-0.34

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for EWTX yet. Check out our latest market news or earnings calendar.

Get EWTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Edgewise Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.